IP Library Granted Patent US 11,919,838
Granted Patent B2
US 11,919,838 · App. 17/305,537 · Granted Mar 5, 2024

Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17

Inventors: Eric Anderson (Southlake, TX); Xin Jiang (Coppell, TX); Melean Visnick (Irving, TX)
Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
C07C255/47C07C271/24C07C275/26C07C275/34C07C311/07C07C311/09C07C311/10C07D209/56C07D211/44C07D231/12C07D261/08C07D261/20C07D295/195C07D295/215C07D307/20C07D333/34C07D487/08C07J63/008C07C2603/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,919,838
App. No.
17/305,537
Granted
Mar 5, 2024
Kind
B2
Abstract

This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

Claims (26)

1. A method of activating the antioxidant/anti-inflammatory Keap1/Nrf2/ARE pathway in a cell, the method comprising contacting the cell with an effective amount of a compound of the formula:

wherein:

R 1 and R 2 are independently:

hydrogen; or

alkyl (c≤12) , alkenyl (c≤12) , alkynyl (c≤12) , aryl (c≤12) , aralkyl (c≤12) , heteroaryl (c≤12) , heteroaralkyl (c≤12) , acyl (c≤12) , alkylsulphonyl, alkenylsulphonyl (c≤12) , alkynylsulphonyl (c≤12) , arylsulphonyl (c≤12) , aralkylsulphonyl (c≤12) , heteroarylsulphonyl (c≤12) , heteroaralkyl-sulphonyl (c≤12) , or a substituted version of any of these groups;

or pharmaceutically acceptable salts, tautomers, or optical isomers thereof.

2. The method of claim 1 , wherein the bond joining carbon 9 and carbon 11 of the compound is a double bond.

3. The method of claim 1 , wherein the bond joining carbon 9 and carbon 11 of the compound is a single bond.

4. The method of claim 1 , wherein the cell is located in a subject, wherein the compound is administered to the subject systemically.

5. The method of claim 4 , wherein the compound is administered to the subject intravenously, intra-arterially, intramuscularly, intraperitoneally, subcutaneously or orally.

6. The method of claim 1 , wherein the cell is located in a subject, wherein the compound is administered to the subject in an amount of 0.1-1000 mg/kg.

7. The method of claim 6 , wherein the compound is administered to the subject in a single dose per day.

8. The method of claim 6 , wherein the compound is administered to the subject in two or more doses per day.

9. A method of reducing oxidative stress in a cell, the method comprising contacting the cell with an effective amount of a compound of the formula:

wherein:

R 1 and R 2 are independently:

hydrogen; or

alkyl (c≤12) , alkellyl (c≤12) , alkynyl (c≤12) , aryl (c≤12) , aralkyl (c≤12) , heteroaryl (c≤12) , heteroaralkyl (c≤12) , acyl (c≤12) , alkylsulphonyl, alkenylsulphonyl (c≤12) , alkynylsulphonyl (c≤12) , arylsulphonyl (c≤12) , aralkylsulphonyl (c≤12) , heteroarylsulphonyl (c≤12) , heteroaralkyl-sulphonyl (c≤12) , or a substituted version of any of these groups;

or pharmaceutically acceptable salts, tautomers, or optical isomers thereof.

10. The method of claim 9 , wherein the bond joining carbon 9 and carbon 11 of the compound is a double bond.

11. The method of claim 9 , wherein the bond joining carbon 9 and carbon 11 of the compound is a single bond.

12. The method of claim 9 , wherein the cell is located in a subject, wherein the compound is administered to the subject systemically.

13. The method of claim 12 , wherein the compound is administered to the subject intravenously, intra-arterially, intramuscularly, intraperitoneally, subcutaneously or orally.

14. The method of claim 9 , wherein the cell is located in a subject, wherein the compound is administered to the subject in an amount of 0.1-1000 mg/kg.

15. The method of claim 14 , wherein the compound is administered to the subject in a single dose per day.

16. The method of claim 14 , wherein the compound is administered to the subject in two or more doses per day.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0130 →
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0228 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Jul 12, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064264/0557 →
PATENT SECURITY AGREEMENT Recorded May 18, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063697/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2022
From: REATA PHARMACEUTICALS, INC.
To: REATA PHARMACEUTICALS HOLDINGS, LLC
Reel/Frame 058639/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2021
From: ANDERSON, ERIC; JIANG, XIN; VISNICK, MELEAN
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 056800/0638 →
Continuity (10)
Continuation 16786429 · Feb 10, 2020
Continuation 16115028 · Aug 28, 2018
Continuation 15615393 · Jun 6, 2017
Continuation 14753297 · Jun 29, 2015
Continuation 13861208 · Apr 11, 2013
Continuation 13356455 · Jan 23, 2012
Continuation 12426778 · Apr 20, 2009
Provisional Application 61111269 · Nov 4, 2008
Provisional Application 61046342 · Apr 18, 2008
Related Publication 20220024862A1 · Jan 27, 2022
Cited By (1)
US 12,384,815